Coherus Oncology is a commercial-stage immuno-oncology company focused on developing and commercializing proprietary cancer medicines. The company's flagship product is LOQTORZI, a PD-1 inhibitor approved for nasopharyngeal carcinoma that is the only immunotherapy option available in the U.S. market for this indication and generates revenue through specialty distribution channels. Beyond LOQTORZI, the company maintains a pipeline of investigational immuno-oncology candidates, including casdozokitug targeting IL-27 and tagmokitug targeting CCR8, which are being evaluated in combination with LOQTORZI and other agents across multiple cancer types. Revenue is generated through direct LOQTORZI sales supplemented by milestone payments and royalties from its collaboration with Junshi Biosciences and territorial licensing arrangements.